10-Q · June 8, 2026
Seaport Therapeutics reported a significant increase in net loss for Q1 2026, reaching $25.4 million compared to a loss of $13.1 million a year earlier. While revenues for the period remain nonexistent, R&D expenses…
Earnings analysis · 10-Q
SPTX earnings analysis
Filed August 3, 2026 · Our reading of the company's report
The latest report
Seaport remains a pre-revenue clinical-stage company, reporting Q2 revenue of $0 and a GAAP loss per share of $1.78, versus a $15.1 million net loss in the prior-year quarter. The quarterly loss expanded to $62.6…
Read full summary
Seaport remains a pre-revenue clinical-stage company, reporting Q2 revenue of $0 and a GAAP loss per share of $1.78, versus a $15.1 million net loss in the prior-year quarter. The quarterly loss expanded to $62.6 million, largely reflecting a $36.0 million IPO-related non-cash stock-compensation charge and higher clinical R&D, while operating cash use was $46.3 million for the first half. The $427.3 million liquidity balance provides a stated runway into 2029, but investment performance remains dependent on clinical readouts beginning in 2H 2026 and BUOY-1 in 1H 2027.
Reported figures
- Earnings per share
- $-1.78
What stood out
-
IPO supports runway into 2029
Cash, cash equivalents and investments were $427.3 million at June 30, 2026 following $238.4 million of net IPO proceeds, which management believes funds operations and capital expenditures into 2029.
-
Near-term clinical catalysts remain on track
GlyphAllo's Phase 2b BUOY-1 trial remains underway, with topline data anticipated in the first half of 2027; a Phase 1 driving-simulation study is expected to report topline data in the second half of 2026.
-
GlyphAgo pharmacokinetic data were favorable
GlyphAgo Phase 1 data showed a 6.8-fold bioavailability increase versus oral agomelatine and 10-fold lower pharmacokinetic variability, with no liver-related adverse events reported in the seven-day MAD portion.
-
R&D investment accelerated for lead program
R&D spending rose $11.2 million year over year to $24.6 million in Q2, led by an $8.0 million increase for GlyphAllo as BUOY-1 and supporting studies advanced.
-
Loss was materially affected by non-cash SBC
The $62.6 million quarterly net loss included $36.0 million of non-cash G&A stock-based compensation, primarily from IPO-related award vesting and acceleration.
What to watch
-
Losses and operating expense rose sharply
Q2 net loss widened to $62.6 million, or $1.78 per share, from $15.1 million a year earlier; total operating expenses increased $47.3 million to $65.8 million.
-
Cash burn and eventual financing need remain
Operating cash use increased $10.8 million year over year to $46.3 million for the first six months of 2026. Although liquidity was $427.3 million, management states it will need substantial additional capital in the future.
-
Clinical execution remains the key valuation risk
The filing highlights potential clinical-timing risk: BUOY-1 topline data are not expected until the first half of 2027, while the company reported an accumulated deficit of $202.1 million at June 30, 2026 and no product revenue.
-
China sourcing and policy risk is highlighted
Risk-factor disclosure flags potential supply-chain exposure from foreign providers and proposed BIOSECURE 2.0 restrictions; the company states it does business with companies in China, while its 2026 operating plan depends on external CROs and manufacturers.
Management's outlook
No revenue or EPS guidance was provided. Management expects $427.3 million of cash, cash equivalents and investments at June 30, 2026 to fund operating expenses and capital expenditures into 2029; clinical timing targets include GlyphAllo driving-simulation data in 2H 2026 and BUOY-1 topline data in 1H 2027.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.